1. Home
  2. NEXN vs DRUG Comparison

NEXN vs DRUG Comparison

Compare NEXN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexxen International Ltd. American Depository Shares

NEXN

Nexxen International Ltd. American Depository Shares

HOLD

Current Price

$6.66

Market Cap

367.2M

Sector

Technology

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$84.66

Market Cap

364.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXN
DRUG
Founded
2007
2019
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
367.2M
364.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NEXN
DRUG
Price
$6.66
$84.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
8
Target Price
$12.13
$83.00
AVG Volume (30 Days)
361.0K
156.6K
Earning Date
11-13-2025
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
237.45
N/A
EPS
0.62
N/A
Revenue
$376,353,000.00
N/A
Revenue This Year
$5.43
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.51
N/A
Revenue Growth
7.80
N/A
52 Week Low
$6.08
$23.18
52 Week High
$12.60
$97.75

Technical Indicators

Market Signals
Indicator
NEXN
DRUG
Relative Strength Index (RSI) 45.03 59.78
Support Level $6.40 $77.80
Resistance Level $6.95 $97.75
Average True Range (ATR) 0.22 8.60
MACD 0.06 -0.54
Stochastic Oscillator 38.81 48.89

Price Performance

Historical Comparison
NEXN
DRUG

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: